(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 36.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.94%.
Cartesian Therapeutics's revenue in 2024 is $26,004,000.On average, 2 Wall Street analysts forecast RNAC's revenue for 2024 to be $332,264,565, with the lowest RNAC revenue forecast at $107,965,740, and the highest RNAC revenue forecast at $556,563,390. On average, 1 Wall Street analysts forecast RNAC's revenue for 2028 to be $82,593,791, with the lowest RNAC revenue forecast at $82,593,791, and the highest RNAC revenue forecast at $82,593,791.
In 2029, RNAC is forecast to generate $487,465,316 in revenue, with the lowest revenue forecast at $487,465,316 and the highest revenue forecast at $487,465,316.